Cross-neutralization effect of the third dose of inactivated COVID-19 vaccine against the SARS-CoV-2 variants
Background The ongoing emergence of SARS-CoV-2 variants has raised concerns about the breadth of the immune response provided by existing vaccines.Research design and methods In this study, participants aged 18-75 years with no prior COVID-19 infection or vaccination history were enrolled to receive...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Expert Review of Vaccines |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/14760584.2025.2550984 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background The ongoing emergence of SARS-CoV-2 variants has raised concerns about the breadth of the immune response provided by existing vaccines.Research design and methods In this study, participants aged 18-75 years with no prior COVID-19 infection or vaccination history were enrolled to receive the CoronaVac vaccine. The interval between the first and second vaccine doses was 28 days, while the third dose was given 6 months after the second.Results Between February 1 to 15 February 2022, we recruited 40 eligible participants who had not received any COVID-19 vaccination and had no prior COVID-19 infection. After the third dose, neutralizing antibody levels significantly increased against the ancestral strain and certain Omicron variants (BA.1, BA.4/5, BF.7). Compared to levels observed 28 days post-second dose, neutralizing antibody levels rose further 28 days after the third dose, with the GMFI against the ancestral strain at 1.69 (95% CI: 1.27, 2.20). Among other variants, the GMFI against Omicron variants (BA.1, BA.4/5, BF.7) exceeded that for Beta and Delta, with the highest GMFI recorded for the BA.4/5 variant at 4.97 (95% CI: 3.08, 8.05).Conclusions The necessity of the third booster dose lies in its ability to enhance the breadth of the immune response. |
|---|---|
| ISSN: | 1476-0584 1744-8395 |